Liste des communications impliquant des médecins

Liste des communications impliquant des médecins de l’Institut Curie au San
Antonio Breast Cancer Symposium qui s’est déroulé du 9 au 13 décembre 2014
Posters
Prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph
node status in breast cancer patients with metastatic sentinel lymph nodes: The MSKCC nomogram and
the Tenon score - PHRC-NOTEGS study
Rouzier R, Uzan C, Rousseau A, Guillot E, Zilberman S, Meyer C, Estevez P, Dupre P-F, Kere D, Doridot V,
D'halluin G, Fritel X, Pouget N, Mazouni C, Simon T, Coutant C.
Institut Curie, Paris, France; Gustave Roussy, Villejuif, France; APHP, Paris, France; Hôpitaux Civils de Colmar, Colmar, France; CHU
Brest, Brest, France; Institut Jean Godinot, Reims, France; Centre Médical République, Clermont-Ferrand, France; Centre Clinical
Soyaux, Soyaux, France; CHU Poitiers, Poitiers, France; Centre Georges-François Leclerc, Dijon, France.
Identification of specific gene signatures and alternative splice variants using exon array in Inflammatory
breast Cancer
Lerebours F, Vacher S, Le Cann M, Rondeau S, Gentien D, Van Laere S, Bertucci F, de la Grange P, Bieche I.
Institut Curie-Hopital Rene Huguenin, Saint-Cloud, France; Institut Curie, Paris, France; General Hospital Sint Augustinus, Wilrijk,
Belgium; Institut Paoli Calmette, Marseille, France; Genosplice, ICM, Hopital Pitie Salpetriere, Paris, France.
Circulating tumor cells (CTC) and endothelial cells (CEC) changes in HER2 negative metastatic breast cancer
(MBC) patients treated with first line weekly paclitaxel and bevacizumab: Preliminary results of a
prospective cohort from the French Breast Cancer InterGroup Unicancer: COMET study
Pierga J-Y, Vaucher I, Gutierrez M, Tredan O, Guiu S, Romieu G, Goncalves A, Debled M, Levy C, Ferrero J-M,
Jouannaud C, Luporsi E, Mouret-Reynier M-A, Dalenc F, Asselain B, Lemonnier J, Bidard F-C.
Institut Curie, Paris, France; Institut Curie, St Cloud, France; Centre Leon Berard, Lyon, France; Centre Georges François Leclerc, Dijon,
France; ICM Val D'Aurelle, Montpellier, France; Institut Paoli Calmettes, Marseille, France; Institut Bergonié, Bordeaux, France;
Centre François Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; ICL Alexis
Vautrin, Vandoeuvre les Nancy, France; Centre Jean Perrin, Clermont-Ferrand, France; Institut Claudius Regaud, Toulouse, France;
R&D UNICANCER, Paris, France
Role of disseminated tumor cell (DTC) in bone marrow (BM) detected at primary diagnosis on overall
survival and central nervous system (CNS) recurrences in a cohort of 620 early breast cancer patients after
11 years follow up
Loirat D, Bidard F-C, Chaltiel L, Berger F, Dieras V, de Rycke Y, Alran S, Kirova Y, Cottu P, Vincent- Salomon A,
Sastre-Garau X, Pierga J-Y.
Institut Curie, Paris, France.
Axillary lymph node metastasis after neoadjuvant chemotherapy: A central prognosis determinant of
triple-negative breast cancers
Bonsang-Kitzis H, Belin L, Pierga J-Y, Chaltiel L, Asselain B, Rouzier R, Cottu P, Sablin M-P, Bidard F-C, Laé M,
Sastre X, Houvenaeghel G, Reyal F.
Department of Surgery, Institut Curie, Paris, France; Department of Biostatistic, Institut Curie, Paris, France; Department of Medical
Oncology, Institut Curie, Paris, France; Department of Tumor Biology, Institut Curie, Paris, France; Department of Surgery, Institut
Paoli Calmettes, Marseille, France; Translational Research Department, RT2Lab Team, Institut Curie, Paris, France.
Clinico-biological characteristics of patients surviving more than two years with metastatic breast cancer
(MBC): Results of a transversal national multicentric survey
Loirat D, Tlemsani C, Arrondeau J, Bellesoeur A, Le Tourneau C, Rousseau B.
Institut Curie, Paris, France; AERIO, Paris, France
Final results of the phase I "HIT" study: A multicenter phase I-II study evaluating trastuzumab
administered by intrathecal injection for leptomeningeal meningitis of HER2+ metastatic breast cancer
(MBC)
Gutierrez M, Mouret Fourme E, Le Rhun E, Tredan O, Dieras V, Tresca P, Mefti F, Turbiez I, Taillibert S,
Desvignes C, Paintaud G.
Curie, Saint Cloud, Ile de France, France; Oscar Lambret, Lille, Picardie, France; Leon Berard, Lyon, France; Tours Hospital, Tours,
France.
Efficacy and tolerance of everolimus in 123 consecutive very advanced luminal breast cancer patients. A
multicenter retrospective study
Chocteau-Bouju D, Chakiba C, Mignot L, Madranges N, Pierga J-Y, Beuzeboc P, Quenel-Tueux N, Diéras V,
Bonnefoi H, Debled M, Cottu PH.
Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; CHRU Bretonneau, Tours, France.
Dual HER2 blockade of an activating driver HER3 mutation: A proof of principle study in a metastatic
breast cancer patient
Bidard F-C, Ng C, Tulukcuoglu E, Piscuoglio S, Descroix S, Mignot L, Viovy J-L, Cottu P, Sigal B, VincentSalomon A, Weigelt B, Pierga J-Y, Reis-Filho J.
Institut Curie, Paris, France; Memorial Sloan Kettering Cancer Center, New-York.
Predictive and prognostic value of triple-negative breast cancers molecular subtypes
Bonsang-Kitzis H, Laurent C, Sadacca B, Pinheiro A, Moarii M, Reyal F.
Translational Research Department, RT2Lab Team, Institut Curie, Paris, France; Department of Surgery, Institut Curie, Paris, France.
Can proton therapy for localized mediastinal Hodgkin's lymphoma reduce second breast cancer incidence?
Horn SR, Pernin V, Fournier-Bidoz N, Kirova Y.
Institut Curie, Paris, France.
TP53 mutants in circulating tumor DNA and follow-up of BRCA1 mutation carriers: The CirCA01 study
Bidard F-C, Stoppa-Lyonnet D, Nogues C, Caron O, Delaloge S, Dugast C, Lasset C, Berger F, Asselain B, Lantz
O, Stern M-H, Pierga J-Y.
Institut Curie, Paris, France; Institut Curie, Saint Cloud, France; Gustave Roussy, Villejuif, France; Centre Eugène Marquis, Rennes,
France; Centre Léon Bérard, Lyon, France.
NEOPAL: A randomized phase II study comparing RCB response to neoadjuvant chemotherapy or
letrozole-palbociclib in PAM50 defined postmenopausal luminal breast cancer
Cottu PH, Duhoux F, Lemonnier J, Bonnefoi H, Vincent Salomon A, Asselain B, Delaloge S.
Institut Curie, Paris, France; Unicancer, Paris, French Polynesia; Institut Bergonie, Bordeaux, France; Institut Gustave Roussy, Villejuif,
France.
ASTER 70s UNICANCER phase III trial: Can a genomic prognosticator help tailoring adjuvant systemic
treatment for luminal breast carcinoma in elderly women?
Dubot C, Bourbouloux E, Mir O, Kirscher S, Rigal O, Ferrero J-M, Cure H, Blot E, Allouache D, Cottu P, Romieu
G, Lefeuvre C, Malaurie E, Tubiana-Mathieu N, Lacroix-Triki M, Rollot F, Peyro-Saint-Paul H, Orsini C,
Bonnetain F, Brain E.
Institut Curie - Site Saint Cloud, Saint-Cloud, France; Institut de Cancérologie de l'Ouest, Nantes, France; Gustave Roussy Cancer
Campus Grand Paris, Villejuif, France; Instituts de cancérologie d'Avignon, Avignon, France; Centre Henri Becquerel, Rouen, France;
Centre Antoine-Lacassagne, Nice, France; Institut Jean Godinot, Reims, France; Centres hospitalier de Vannes, Vannes, France;
Centre François Baclesse, Caen, France; Institut Curie - Site Paris, Paris, France; Institut régional du Cancer Montpellier, Montpellier,
France; Centre Eugène Marquis, Rennes, France; CHI de Créteil, Créteil, France; CHU de Limoges, Limoges, France; Institut
Universitaire du Cancer Toulouse - Oncopole, Toulouse, France; QIAGEN Marseille SA, Marseille, France; UNICANCER, Paris, France;
CHU Besançon, Besancon, France.
Poster Discussion
Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients
Bidard F-C, Madic J, Kiialainen A, Birzele F, Ramey G, Leroy Q, Rio Frio T, Raynal V, Bernard V, Lermine A,
Clausen I, Giroud N, Schmucki R, Horn C, Spleiss O, Lantz O, Stern M-H, Weisser M, Lebofsky R, Pierga J-Y.
Institut Curie, Paris, France; Roche Pharma Research and Early Development (pRED), Innovation Center, Basel, Switzerland; Institut
Roche de Recherche et Médecine Translationnelle, Boulogne-Billancourt, France; Roche Pharma Research and Early Development
(pRED), Innovation Center, Penzberg, Germany.
Présentation orale avec en co-auteur des médecins de l’Institut Curie
The genomic landscape of male breast cancers.
Piscuoglio S, Murray M, Ng CKY, Guerini Rocco E, Martelotto LG, Bidard FC, Eberle CA, Fusco N, Sakr RA, De
Mattos-Arruda L, Lim R, Baslan T, Hicks J, King TA, Brogi E, Norton L, Weigelt B, Hudis CA, Reis-Filho JS.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; School of Pathology, University of Milan, Milan,
Italy; Institut Curie, Paris, France; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Posters avec en co-auteur des médecins de l’Institut Curie
Mesenchymal stem cell regulated microRNAs converge on the speech gene FOXP2 and regulate breast
cancer metastasis
Cuiffo BG, Campagne A, Bell GW, Lembo A, Orso F, Lien E, Bhasin MK, Raimo M, Hanson SE, Marusyk A,
Hematti P, Polyak K, Mariani O, Volinia S, Vincent-Salomon A, Taverna D, Karnoub AE.
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Institut Curie, Paris, France; Whitehead Institute for
Biomedical Research, Cambridge, MA; University of Turin and MBC Via Nizza, Torino, Italy; University of Wisconsin-Madison, School
of Medicine and Public Health, Madison, WI; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; University of
Ferrara, Ferrara, Italy; Harvard Stem Cell Institute, Cambridge, MA; Broad Institute of MIT and Harvard, Cambridge, MA.
Sentinel node surgery after neoadjuvant chemotherapy in patient with axillary node involvement: The
French GANEA 2 prospective multi-institutional trial
Classe J-M, Campion L, Alran S, Tunon de Lara C, Dupre PF, Faure C, Paillocher N, Lasry S, Chauvet MP,
Houvenaeghel G, Gutowski M, De Blaye P, Ngo C, Barranger E, Veraeghe JL, Lefebvre C, Rodier JF, Bordes V,
Charitansky H, Ferron G, Gimbergues P.
Institut de Cancerologie de l'Ouest, Saint Herblain, France; Institut Curie, Paris, France; Institut Bergonié, Bordeaux, France; CHU
Morvan, Brest, France; Centre Leon Berard, Lyon, France; Centre Oscar Lambret, Lille, France; Institut Paoli Calmette, Marseille,
France; Centre Valdorel, Montpellier, France; CH Les oudairies, La Roche sur Yon, France; Hopital europeen georges pompidou, Paris,
France; Centre Lacassagne, Nice, France; Centre Alexis vautrin, Nancy, France; CHU Angers, Angers, France; Centre Paul Strauss,
Strasbourg, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont Ferrand, France.
Mutational landscape of metaplastic breast carcinomas
Ng CKY, Weigelt B, Piscuoglio S, Wen YH, De Filippo MR, Martelotto LG, Natrajan R, Lim R, Brogi E, Norton L,
Vincent-Salomon A, Reis-Filho JS.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre,
The Institute of Cancer Research, London, United Kingdom; Department of Medicine, Memorial Sloan Kettering Cancer Center, New
York, NY; Institut Curie, Paris, France
Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III
trial: Maintenance bevacizumab (BEV) ± capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC)
for HER2-negative metastatic breast cancer (mBC)
Doval D, Cinieri S, Bozcuk H, Pierga J-Y, Altundag K, Wang X, Gupta S, Lopez Vivanco G, Gupta V,
Chmielowska E, Bines J, Montcuquet P, Namour A, Alba E, Mustacchi G, Cortes P, de Ducla S, Freudensprung
U, Fallowfield L, Gligorov J.
Rajiv Gandhi Cancer Institute & Research Center, Delhi, India; Medical Oncology Department and Breast Unit, Brindisi, Italy; Akdeniz
University Medical Faculty, Antalya, Turkey; Institut Curie, Université Paris Descartes, Paris, France; Hacettepe University Cancer
Institute, Ankara, Turkey; Zhejiang Cancer Hospital, Hangzhou City, China; Tata Memorial Hospital/Center, Mumbai, India; Hospital
Universitario Cruces, Vizcaya, Spain; Bangalore Institute of Oncology, Bangalore, India; Centrum Onkologii Prof. F Lukaszczyka,
Bydgoszcz, Poland; Instituto Nacional de Cancer, Rio de Janeiro, Brazil; Clinique Saint Vincent, Besançon, France; National Cancer
Institute, Cairo University, Cairo, Egypt; Hospital University Clinic Virgen de la Victoria, Málaga, Spain; Medical Oncology, University
of Trieste, Trieste, Italy; University Hospital of Santa Maria, Lisbon, Portugal; F Hoffmann-La Roche Ltd, Basel, Switzerland; Brighton &
Sussex Medical School, University of Sussex, Falmer, United Kingdom; APHP Tenon, IUC-UPMC, Paris, France.
Overall survival (OS) in the IMELDA randomized phase III trial of maintenance bevacizumab (BEV) with or
without capecitabine (CAP) for HER2-negative metastatic breast cancer (mBC)
Gligorov J, Bines J, Alba E, Mustacchi G, Cinieri S, Gupta V, Pierga J-Y, Bozcuk H, Gaafar R, Gupta S, Lopez
Vivanco G, Wang X, Costa R, Altundag K, Chmielowska E, de Ducla S, Freudensprung U, Cortes P, Doval D.
APHP Tenon, IC-UPMC, Paris, France; Instituto Nacional de Cancer, Rio de Janeiro, Brazil; Hospital University Clinic Virgen de la
Victoria, Málaga, Spain; Medical Oncology, University of Trieste, Trieste, Italy; Medical Oncology Department and Breast Unit,
Brindisi, Italy; Bangalore Institute of Oncology, Bangalore, India; Institut Curie, Université Paris Descartes, Paris, France; Akdeniz
University Medical Faculty, Antalya, Turkey; National Cancer Institute, Cairo University, Cairo, Egypt; Tata Memorial Hospital/Center,
Mumbai, India; Hospital Universitario Cruces, Vizcaya, Spain; Zhejiang Cancer Hospital, Hangzhou City, China; Instituto do Câncer do
Estado de São Paulo, São Paulo, Brazil; Hacettepe University Cancer Institute, Ankara, Turkey; Centrum Onkologii Prof. F Lukaszczyka,
Bydgoszcz, Poland; F Hoffmann-La Roche Ltd, Basel, Switzerland; University Hospital of Santa Maria, Lisbon, Portugal; Rajiv Gandhi
Cancer Institute & Research Center, Delhi, India.
“BEECH", a phase 1/2 study of the AKT inhibitor AZD5363 combined with paclitaxel in patients with
advanced or metastatic breast cancer: Results from the dose-finding study including quantitative
assessment of circulating tumour DNA as a surrogate for response/resistance
Turner N, Oliveira M, Armstrong A, Sablin M-P, Perez-Fidalgo J, Hrebien S, Garcia-Murillas I, Johnson S, Foxely
A, Mahmood A, Lindemann J.
Royal Marsden Hospital NHS Trust, London, United Kingdom; Vall d'Hebron University Hospital, Barcelona, Spain; Christie Hospital
NHS Foundation Trust, Manchester, United Kingdom; Institue Curie, Paris, France; Hospital Clinico Universitario, Valencia, Spain;
Institute of Cancer Research, London, United Kingdom; Astra Zeneca, Macclesfield, United Kingdom.
Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in
patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or
lapatinib-based therapy: LUX-Breast 3
Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espie M, Kim S-B, Schneeweiss A, Sohn JH,
Nabholtz J-M, Kellokumpu-Lehtinen P-L, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F,
Joensuu H.
Hospital Universitari Vall d'Hebron, Barcelona, Spain; Institut Curie, Paris, France; National Cancer Center, Goyang-si, Republic of
Korea; Centre Antoine Lacassagne, Nice, France; Centre Léon Bérard, Lyon, France; TRIO-US Network, Los Angeles; Centre Oscar
Lambret and University Hospital, Lille, France; Hôpital Saint-Louis, Paris, France; Asan Medical Center, Seoul, Republic of Korea;
National Center for Tumor Diseases, Heidelberg, Germany; Severance Hospital, Seoul, Republic of Korea; Centre Jean Perrin,
Clermont-Ferrand, France; Comprehensive Cancer Center, Helsinki, Finland; Sansum Clinic, Santa Barbara; Università di Modena e
Reggio Emilia, Modena, Italy; Hospital Universitario 12 de Octubre, Madrid, Spain; Boehringer Ingelheim, Paris, France; Boehringer
Ingelheim, Reims, France.
The multidisciplinary application of genomics in clinical practice (MAGIC) survey: Identification of early
stage hormone receptor-positive (HR+), HER2- breast cancer (BC) patients in whom multigene assays
may have their highest utility
Aapro M, Bargallo Rocha JE, De Laurentiis M, Elizalde R, Landherr L, Linderholm B, Mamounas T,
Markopoulos C, Martin M, Neven P, Petrovsky A, Rea D, Rouzier R, Smit V, Svedman C, Thomssen C.
Multidisciplinary Oncology Institute, Clinic of Genolier, Genolier, Switzerland; Department of Surgery, Instituto Nacional de
Cancerologia, Mexico City, Mexico; Department of Senology, National Cancer Institute G. Pascale Foundation, Naples, Italy; División
Ginecologia y Mastologia, Hospital Dr. I. Pirovano, Buenos Aires, Argentina; Department of Oncoradiology, Uzsoki Teaching Hospital,
Budapest, Hungary; Department of Oncology, Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; University of
Florida Health Cancer Center at Orlando Health, Orlando, FL; Department of Surgery, Athens University Medical School, Athens,
Greece; Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Multidisciplinary Breast Centre
and Gynaecological Oncology, UZ Leuven, Leuven, Belgium; Department of Radiosurgery, Russian Cancer Research Center, Moscow,
Russian Federation; School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Surgery,
Institut Curie-Université Versailles-Saint-Quentin, Paris-Saint-Cloud, France; Department of Pathology, Leiden University Medical
Center, Leiden, Netherlands; Medical Affairs, Genomic Health, Stockholm, Sweden; Department of Gynecology, Martin-LutherUniversity Halle-Wittenberg, Halle (Saale), Germany.
Phase 1/2a study of glutathione PEGylated liposomal doxorubicin (2B3-101) in breast cancer patients with
brain metastases
Aftimos PG, Milojkovic-Kerklaan B, Diéras V, Altintas S, Anders C, Arnedos M, Gelderblom H, Soetekouw P,
Gladdines W, Gaillard P, de Sousa C, Jager A, van Linde M, Awada A, Schellens J, Brandsma D.
Institut Jules Bordet, Université Libre de Bruxelles, Medical Oncology Clinic, Brussels, Belgium; Netherlands Cancer Institute - Antoni
van Leeuwenhoek Hospital, Department of Clinical Pharmacology, Amsterdam, Netherlands; Institute Curie, Department of Medical
Oncology, Paris, France; Antwerp University Hospital, Department of Medical Oncology, Antwerp, Belgium; Lineberger
Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC; Gustave Roussy Cancer Institute,
Department of Medical Oncology, Villejuif, France; Leiden University Medical Center, Department of Clinical Oncology, Leiden,
Netherlands; Maastricht University Medical Center, Department of Medical Oncology, Maastricht, Netherlands; to-BBB technologies
B.V., R&D Department, Leiden, Netherlands; Erasmus MC, Daniel den Hoed Oncology Center, Rotterdam, Netherlands; VU Medical
Center, Department of Medical Oncology, Amsterdam, Netherlands; Netherlands Cancer Institute – Antoni van Leeuwenhoek
Hospital, Department of Neuro-Oncology, Amsterdam, Netherlands.
Trastuzumab in HER2-negative early breast cancer as adjuvant treatment for circulating tumor cells (CTCs)
(Treat CTC)
Ignatiadis M, Messina C, Litiere S, Mavroudis D, Dittrich C, Kong A, Janni W, Sotiriou C, Piccart M, Pierga J-Y,
Rack B.
Institut Jules Bordet, Université Libre de Bruxelles, Belgium; European organization for research and treatment of cancer (EORTC),
Belgium; University Hospital of Heraklion, Greece; LBI-ACR VIEnna – LBC-TO, Kaiser Franz Josef-Spital, Austria; Oxford University
Hospitals NHS Trust - Churchill Hospital, United Kingdom; Universitätsklinikum Ulm, Germany; Institut Curie, France; LudwigMaximilians-University, Germany.
Alterations of intratumoral signalling in breast cancer patients receiving pre-operative trastuzumab alone
or combined with everolimus
Merlin J-L, Lion M, Wong J, Bachelot T, Andre F, Treilleux I, Loussouarn D, Bonneterre J, Rios M, Dieras V,
Jimenez M, Leroux A, Campone M.
Institut de Cancérologie de Lorraine, Nancy, France; Institut Curie, Paris, France; Centre Léon Bérard, Lyon, France; Institut Gustave
Roussy, Villejuif, France; Institut de Cancérologie de l'Ouest, Nantes, France; Centre Oscar Lambret, Lille, France; Unicancer R&D,
Paris, France.